Table 1 Clinical and biological characteristics of the study population
From: End stage renal disease patients have a skewed T cell receptor Vβ repertoire
Healthy individuals | ESRD Patients | P value | |
|---|---|---|---|
Number of individuals | 51 | 45 | |
Age (young/eldely) (years; mean ± SD) | 33.1 ± 7.6/68.0 ± 3.0 | 32.9 ± 9.2 / 68.3 ± 3.5 | NS/NSa |
Sex (% male) | 41.2 | 68.9 | P < 0.05 |
CMV IgG serostatus (% pos) | 52.9 | 51.1 | NS |
T cells number in peripheral blood (106/μl; mean ± SD) | 1274 ± 304 | 1164 ± 260 | NS |
Renal replacement therapy (number; %) | 44.4 | ||
Duration of Renal replacement therapy (months; median/rang) | 13/3-68 | ||
Hemodialysis (%) | 80.0 | ||
Peritoneal dialysis (%) | 15.0 | ||
Peritoneal dialysis followed hemodialysis (%) | 5.0 | ||
Underlying kidney disease | |||
Nephrosclerosis/atherosclerosis/hypertensive nephropathy (%) | 17.8 | ||
Primary glomerulopathy (%) | 6.7 | ||
Diabetic nephropathy (%) | 20.0 | ||
Reflux nephropathy (%) | 17.8 | ||
Polycystic kidney disease (%) | 20.0 | ||
Other (%) | 15.6 | ||
Unknown (%) | 2.2 |